U.S. Food and Drug Administration Approves IMBRUVICAâ„¢ (ibrutinib) as a Single Agent for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy

[PR Newswire] – SUNNYVALE, Calif., Feb. 12, 2014 /PRNewswire/ — Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA â„¢ (ibrutinib) as a single agent … more

View todays social media effects on PCYC

View the latest stocks trending across Twitter. Click to view dashboard

See who Pharmacyclics is hiring next, click here to view